Use of alfuzosin 10 mg once daily increases the likelihood of a successful trial without catheter (TWOC) after acute urinary retention (AUR) secondary to benign prostatic hyperplasia (BPH), according to researchers.
Ho Yee Tiong, MD, and colleagues at the National University Hospital of Singapore, studied 67 men who were catheterized for an initial episode of AUR secondary to BPH. They randomly assigned subjects to receive alfuzosin 10 mg once daily or placebo for two days. Sixty-four patients completed the trial.
Of the 35 men in the alfuzosin group, 21 (60%) had a successful TWOC compared with 11 of 32 placebo recipients (34%), the investigators reported in Urologia Internationalis (2009; published online ahead of print).
The study also demonstrated that intravesical prostatic protrusion (IPP) greater than 10 mm as measured by transabdominal ultrasonography is an independent negative predictor of successful TWOC in patients treated with alfuzosin. On average, these men were four times less likely to have a successful TWOC after AUR than those with an IPP less than 10 mm, data showed.